IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+8.94%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$241M
AUM Growth
+$241M
(-0.03%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
5.3%
Top 10 Holdings %
Top 10 Hldgs %
40.16%
Holding
106
New
29
Increased
9
Reduced
21
Closed
6
Top Buys
| 1 |
Merck
MRK
|
$10.6M |
| 2 |
BridgeBio Pharma
BBIO
|
$9.86M |
| 3 |
Insmed
INSM
|
$8.27M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$7.32M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$6.6M |
Top Sells
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$17.5M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$10.2M |
| 3 |
Biohaven
BHVN
|
$5.94M |
| 4 |
Celldex Therapeutics
CLDX
|
$5.81M |
| 5 |
89bio
ETNB
|
$5.78M |
Sector Composition
| 1 | Healthcare | 97.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $13.5M | 3.07% | 125,926 -163,000 | -56% | -$17.5M |
|
2
Immunovant
IMVT
$2.56B
| $12M | 2.73% | 774,398 -192,302 | -20% | -$2.98M |
|
3
Astria Therapeutics
ATXS
$349M
| $11.6M | 2.62% | 869,390 +194,214 | +29% | +$2.58M |
|
|
4
Merck
MRK
$210B
| $10.6M | 2.41% | +100,000 | New | +$10.6M |
|
|
5
BridgeBio Pharma
BBIO
$9.89B
| $9.86M | 2.24% | +594,686 | New | +$9.86M |
|
6
Terns Pharmaceuticals
TERN
$609M
| $8.54M | 1.94% | 721,341 -15,978 | -2% | -$189K |
|
7
Vaxcyte
PCVX
$4B
| $8.43M | 1.91% | 225,000 -25,000 | -10% | -$937K |
|
|
8
Insmed
INSM
$28.8B
| $8.27M | 1.88% | +485,000 | New | +$8.27M |
|
|
RETA
9
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $7.32M | 1.66% | +80,564 | New | +$7.32M |
|
|
10
Apellis Pharmaceuticals
APLS
$3.48B
| $6.6M | 1.5% | +100,000 | New | +$6.6M |
|
|
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $6.56M | 1.49% | 283,464 | – | – |
|
12
Biomea Fusion
BMEA
$116M
| $6.54M | 1.48% | +210,975 | New | +$6.54M |
|
|
BLU
13
DELISTED
BELLUS Health Inc.
BLU
| $6.37M | 1.45% | 885,334 | – | – |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $5.74M | 1.3% | 160,486 | – | – |
|
|
15
Biohaven
BHVN
$1.63B
| $5.5M | 1.25% | 402,326 -435,174 | -52% | -$5.94M |
|
|
TCON
16
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $5.23M | 1.19% | 2,765,530 | – | – |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.19M | 1.18% | 213,521 -163,500 | -43% | -$3.98M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.86M | 1.1% | +50,000 | New | +$4.86M |
|
|
VRNA
19
Verona Pharma
VRNA
$9.16B
| $4.59M | 1.04% | 228,677 -26,454 | -10% | -$531K |
|
|
BCYC
20
Bicycle Therapeutics
BCYC
$511M
| $4.41M | 1% | +207,112 | New | +$4.41M |
|
21
Roivant Sciences
ROIV
$8.15B
| $4.24M | 0.96% | +575,000 | New | +$4.24M |
|
22
Arcus Biosciences
RCUS
$1.13B
| $4.2M | 0.95% | 230,000 +92,013 | +67% | +$1.68M |
|
|
JBIO
23
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $3.94M | 0.89% | 195,146 +67,225 | +53% | +$1.36M |
|
24
Merus
MRUS
$4.98B
| $3.84M | 0.87% | 208,650 +52,650 | +34% | +$969K |
|
|
25
Celldex Therapeutics
CLDX
$1.47B
| $3.82M | 0.87% | 106,057 -161,419 | -60% | -$5.81M |
|